GuruFocus · JNJ · October 24, 2026

Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer

Get the app for more

Explore stock news, insights and company research.